Further, physicians see hypoglycaemia as a limiting factor in how aggressively they can use therapies such as insulin (associated with hypoglycaemia) to treat type 2 diabetes (T2D) [19]. The gene discussed is INS; the disease is type 2 diabetes mellitus.